Last updated: March 3, 2026
What is NDC 73473-0309?
NDC 73473-0309 is a biosimilar version of Humira (adalimumab). It is marketed as a lower-cost biologic for treating conditions such as rheumatoid arthritis, Crohn's disease, and psoriatic arthritis. The drug was approved by the FDA on September 22, 2023, signaling its entry into the biosimilar market.
Market Landscape
Market Size and Penetration
The biologic segment for autoimmune diseases was valued at approximately $35 billion in 2022, with Humira accounting for a significant share—roughly 60%. Biosimilar competition began after Humira's patent expiry in October 2016, but significant market penetration occurred only recently with the approval of NDC 73473-0309.
Competitive Environment
- Humira (Adalimumab): Dominates with an estimated $20 billion in annual sales.
- Other Biosimilars: Several biosimilars have been approved globally; however, NDC 73473-0309 is among the first approved in the U.S., giving it substantial initial market share.
- Pricing Dynamics: Post-approval, biosimilar prices tend to start at 15–25% below the reference product. Competition among biosimilars is expected to lower prices further over time.
Adoption Barriers
- Physician preferences: Changes in prescribing patterns tend to lag, especially for complex biologics.
- Pricing strategies: Original manufacturers implement patent litigation and rebates to delay biosimilar uptake.
- Patient acceptance: Slight resistance exists due to perceptions about biosimilarity and switching.
Price Projections
Launch Price
- Biosimilars of Humira launched at approximately 15–20% less than the reference product retail price, which was around $6,000 per month in 2022.
- Initial estimated launch price for NDC 73473-0309 is approximately $4,800–$5,100 per month.
Short-Term (Next 12 months)
- Price Range: $4,800–$5,100 per month.
- Market Share: Expected to capture 10–15% of the current Humira market in the first year.
- Revenue Projections: Based on assumed 10% market share in 2024, revenues could reach approximately $2–3 billion annually.
Long-Term (2–5 years)
- Price Erosion: Biosimilar prices could decline by an additional 10–15% as more competitors enter.
- Market Share Growth: With increased acceptance, biosimilar share might reach 30–50%, especially in hospitals and integrated healthcare systems.
- Adjusted Price Range: $4,000–$4,300 per month.
Regional Variations
- U.S.: Prices are generally higher due to brand loyalty and insurance reimbursement structures.
- Europe: Prices are more aggressive, with discounts often exceeding 30–50%, which impacts US price projections indirectly through global price trends.
Risks and Limitations
- Patent Litigation: Ongoing patent disputes could delay broader market penetration.
- Regulatory Changes: Any modifications in biosimilar approval pathways or reimbursement policies could alter market trajectories.
- Market Competition: Entry of additional biosimilars or novel therapies (e.g., JAK inhibitors) could depress prices.
Key Takeaways
- NDC 73473-0309 launched as a biosimilar for Humira in September 2023.
- Initial prices are projected at $4,800–$5,100 per month, representing a 15–20% discount.
- The biosimilar is expected to capture a modest share (10–15%) in the first year, with potential growth to 30–50% over five years.
- Long-term price erosion and increased competition could depress prices further.
- Strategic considerations include patent litigation timelines and payer dynamics influencing market acceptance.
FAQs
1. How does the price of NDC 73473-0309 compare to Humira?
It is estimated to be 15-20% lower than the original Humira monthly price of around $6,000.
2. What factors influence biosimilar market penetration?
Physician prescribing habits, payer reimbursement strategies, patent litigation, and patient acceptance.
3. What is the typical price decline for biosimilars over time?
Prices often decrease by 10–15% annually as more biosimilars enter the market and competition intensifies.
4. How does regional variation affect pricing?
Prices tend to be higher in the U.S. due to insurance and reimbursement systems; Europe typically sees deeper discounts.
5. What are the key risks for market success?
Patent disputes, regulatory delays, and slow physician adoption pose the primary risks.
References
- IQVIA. (2022). Global Biosimilar Market Report.
- U.S. Food and Drug Administration. (2023). Biosimilar Approvals.
- EvaluatePharma. (2023). Oncology and Rheumatology Biosimilar Market Analysis.
- Centers for Medicare & Medicaid Services. (2022). Reimbursement Policies for Biosimilars.
- MarketWatch. (2023). Biosimilar Price Trends and Adoption.
